Advertisement

Index by author

February 01, 1996; Volume 276,Issue 2

  1. Hamman, M A

    1. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.
      B J Ring, J Catlow, T J Lindsay, T Gillespie, L K Roskos, B J Cerimele, S P Swanson, M A Hamman and S A Wrighton
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 658-666;

  2. Hariman, R J

    1. Cocaine concentration-effect relationship in the presence and absence of lidocaine: evidence of competitive binding between cocaine and lidocaine.
      D Liu, R J Hariman and J L Bauman
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 568-577;

  3. Harmatz, J S

    1. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
      L L von Moltke, D J Greenblatt, J S Harmatz, S X Duan, L M Harrel, M M Cotreau-Bibbo, G A Pritchard, C E Wright and R I Shader
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 370-379;

  4. Harrel, L M

    1. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
      L L von Moltke, D J Greenblatt, J S Harmatz, S X Duan, L M Harrel, M M Cotreau-Bibbo, G A Pritchard, C E Wright and R I Shader
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 370-379;

  5. Hasegawa, T

    1. The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice.
      K Yamada, Y Noda, T Hasegawa, Y Komori, T Nikai, H Sugihara and T Nabeshima
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 460-466;

  6. Hashefi, M

    1. Effects of metabolites of leukotriene B4 on human neutrophil migration and cytosolic calcium levels.
      W S Powell, J Rokach, S P Khanapure, S Manna, M Hashefi, S Gravel, R J Macleod, J R Falck and R K Bhatt
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 728-736;

  7. Hashmi, M

    1. Galactose-modified streptavidin-GC4 antifibrin monoclonal antibody conjugates: application for two-step thrombus/embolus imaging.
      S F Rosebrough and M Hashmi
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 770-775;

  8. Hay, D W

    1. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
      E H Ohlstein, P Nambi, A Lago, D W Hay, G Beck, K L Fong, E P Eddy, P Smith, H Ellens and J D Elliott
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 609-615;

  9. Haynes, J

    1. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
      J Haynes, D W Killilea, P D Peterson and W J Thompson
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 752-757;

  10. Head, G A

    1. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits.
      C K Chan, F Sannajust and G A Head
      Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 411-420;
« Previous (Pages : 1 2 ... 2) Next »
Back to top

In this issue

Advertisement